2008—down, but not out

@article{Yang20092008downBN,
  title={2008—down, but not out},
  author={Walter Yang},
  journal={Nature Biotechnology},
  year={2009},
  volume={27},
  pages={113-113}
}
Researcher Investor Value ($ millions) Deal description Actelion GlaxoSmithKline $3,246.8 Co-develop and co-commercialize phase 3 insomnia compound almorexant outside of Japan Isis Genzyme $1,900.0 Develop mipomersen and follow-on compounds to treat high cholesterol Acceleron Celgene $1,878.0 Jointly develop and commercialize ACE-011 to treat cancer; option… CONTINUE READING